BNP Paribas Financial Markets
AARD

BNP Paribas Financial Markets’s Aardvark Therapeutics AARD Stock Holding History

BNP Paribas Financial Markets’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2K Sell
3,234
-12,622
-80% -$131K ﹤0.01% 5181
2025
Q4 		$208K Sell
15,856
-40,690
-72% -$508K ﹤0.01% 4040
2025
Q3 		$751K Buy
56,546
+21,052
+59% +$237K ﹤0.01% 3328
2025
Q2 		$480K Buy
35,494
+804
+2% +$8.29K ﹤0.01% 3345
2025
Q1 		$261K Buy
+34,690
New +$390K ﹤0.01% 3565

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BNP Paribas Financial Markets's AARD Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Aardvark Therapeutics (AARD) stake by 80% in Q1 2026, selling an estimated $131K and leaving 3,234 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5181.

BNP Paribas Financial Markets first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $751K in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • BNP Paribas Financial Markets held 3,234 shares of Aardvark Therapeutics worth $12.2K as of Q1 2026.
  • BNP Paribas Financial Markets sold 12,622 Aardvark Therapeutics shares in Q1 2026, an estimated $131K.
  • Aardvark Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5181 holding.
  • BNP Paribas Financial Markets first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • BNP Paribas Financial Markets's Aardvark Therapeutics position peaked at $751K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.